Search PubMed⌕ Search

Biomedical subjects

K Imai

Publications and source records attributed to K Imai.

At least 1,297 records · Page 72Linked to original sources
PubMed1985

Immunohistochemical analysis of antimelanoma monoclonal antibodies, with special reference to fetal tissue distribution.

An immunohistochemical study using 2 antihuman melanoma monoclonal antibodies designated as MoAb 225.28S and MoAb 653.40S was carried out on various human skin tumors, including malignant melanoma as well as on normal and fetal tissues by indirect immunofluorescence technique. Specific immunofluorescence was observed not only in malignant melanoma cells but also in cells of pigmented nevi, basal cell epithelioma, normal hair follicles, and some fetal tissues. Both monoclonal antibodies were revealed to be able to recognize the common antigenic determinant shared by several skin tumors, including malignant melanoma, and fetal tissues. Therefore, both monoclonal antibodies might recognize premature antigen of both melanocytic and keratinocytic cell lineage.

Antibodies, Monoclonal↗
PubMed1985

Production of macrophage activating factor by human leukemic T cell lines.

Human leukemic T cell lines were tested for their ability to produce a macrophage activating factor. When mouse peritoneal macrophages were cultured for 48 hr in the presence of culture supernatants from cell lines HPB-ALL, CCRF-CEM, or MOLT-4, glucose oxidation via the hexose monophosphate pathway was enhanced by five to seven fold. Culture supernatants from cell line HPB-MLT stimulated the oxidation to a lesser extent. However, cell line CCRF-HSB-2 was essentially inactive as a producer. The active supernatants also stimulated the release of hydrogen peroxide from macrophages, whereas the inactive one did not. Since treatment of the cell lines with 12-o-tetradecanoyl phorbol acetate or phytohemagglutinin had little effect on the production of the factor except HPB-ALL, the cell lines seemed to secrete the factor constitutively. The stimulatory effect was dose-dependent and evident at a concentration as low as a 1/80 dilution. The factor was resistant to heat treatment at 100 C for 20 min, nondialysable and sensitive to protease digestion. The activating factor could be partially purified by anion exchange and gel filtration chromatographies.

Animals↗
PubMed1985

Role of a Ferric Ion-Reducing System in Sulfur Oxidation of Thiobacillus ferrooxidans.

The properties of a ferric ion-reducing system which catalyzes the reduction of ferric ion with elemental sulfur was investigated with a pure strain of Thiobacillus ferrooxidans. In anaerobic conditions, washed intact cells of the strain reduced 6 mol of Fe with 1 mol of elemental sulfur to give 6 mol of Fe, 1 mol of sulfate, and a small amount of sulfite. In aerobic conditions, the 6 mol of Fe produced was immediately reoxidized by the iron oxidase of the cell, with a consumption of 1.5 mol of oxygen. As a result, Fe production was never observed under aerobic conditions. However, in the presence of 5 mM cyanide, which completely inhibits the iron oxidase of the cell, an amount of Fe production comparable to that formed under anaerobic conditions was observed under aerobic conditions. The ferric ion-reducing system had a pH optimum between 2.0 and 3.8, and the activity was completely destroyed by 10 min of incubation at 60 degrees C. A short treatment of the strain with 0.5% phenol completely destroyed the ferric ion-reducing system of the cell. However, this treatment did not affect the iron oxidase of the cell. Since a concomitant complete loss of the activity of sulfur oxidation by molecular oxygen was observed in 0.5% phenol-treated cells, it was concluded that the ferric ion-reducing system plays an important role in the sulfur oxidation activity of this strain, and a new sulfur-oxidizing route is proposed for T. ferrooxidans.

Journal Article↗
PubMed1985

Adsorption of anionic chloro complexes of 59Fe and 195Au on non-ionic resins of macro-reticular type.

Adsorption behavior of 59Fe and 195Au on the non-ionic macro-reticular resin, Amberlite XAD-7 is studied. Distribution coefficients (Kd) for both nuclides in hydrochloric acid or lithium chloride solutions above 6M are particularly high. In nitric acid solution below 2M, 195Au is highly adsorbed on the resin but 59Fe is negligible over any concentrations. This resin did not adsorb other important radionuclides such as 54Mn, 60Co, 65Zn, 90Sr, 106Ru, 137Cs and 144Ce at all. Based on such peculiar adsorption behavior, application to selective separation and determination of radio and stable iron in sea water was also studied.

Acrylic Resins↗
PubMed1985

Circulating blood group-related antigen(s) in cancer patients detected by the monoclonal antibodies produced against hepatocellular carcinoma cell line.

Two murine monoclonal antibodies (MAbs) S1 and S3 produced against a human hepatoma cell line were found to recognize both H (type II) antigen and difucosyl type II structure (Y-antigen). Both MAbs reacted with hepatoma tissues obtained from surgical resection. A double determinant enzyme immunoassay (DDEI) employing these MAbs successfully detected the corresponding antigen(s) in the supernatant which is either released or shed from the immunizing hepatoma cell line. DDEI also revealed that these antibodies reacted with the corresponding antigen(s) in the sera from cancer patients. Among the sera from O blood group donors, individuals with primary hepatoma showed markedly higher levels of antigen concentration than the normal control group. Several cases with gall bladder, lung and pancreas carcinomas, which are of O blood type, also had significantly higher levels of antigen. One case with ovarian cancer of B blood type showed higher antigen concentration than normal O blood group donors suggesting a change in the carbohydrate structure of the corresponding antigen(s) in the serum. These data suggest that the release or the shedding of the antigen(s) from the cells may increase due to the malignant transformation, resulting in higher amounts of the antigen(s) in the serum of certain cancer patients.

ABO Blood-Group System↗
PubMed1985

[Therapy of renal cell carcinoma. 1. Hormonal therapy].

Sixty eight patients with renal cell carcinoma were treated at our University in 1968 approximately 1983. The prognosis of these patients was studied retrospectively. Sixty six patients had also been receiving treatment with chemotherapy or radiotherapy except 3 cases after radical nephrectomy. Thirty five of the patients with Stage I approximately N renal cell carcinoma were treated with hormonal therapy using chlormadinone acetate (CMA) or medroxyprogesterone acetate (MPA). CMA was used prophylactically in 21 patients with Stage I approximately IIIA renal cell carcinoma and who had undergone radical nephrectomy. Metastasis was noted in 3 cases in this prophylactic CMA group (21 cases) and 4 cases in the control group (19 cases). No significant difference between these two groups was observed statistically. In the advanced group with Stage IIIC-IV renal cell carcinoma (11 cases), only one case with a complete response was noted after CMA combination therapy.

Adult↗
PubMed1985

[Study on voiding disturbance in elderly males. II. Analysis of the patterns in uroflowmetric studies in patients with obstructive diseases in lower urinary tract and neurogenic bladder].

Uroflowmetry was examined in 192 patients with obstructive urinary symptoms. They were 173 males with obstructive diseases in lower urinary tract (302 uroflowmetric studies) and 19 males with neurogenic bladder (29 uroflowmetric studies). We classified the patterns of uroflowmetric curve into 6 types: N type (normal), NB type (neurogenic bladder: wave like curve), OB type (obstructive diseases: flat curve), AP type (anterior peak), PP type (posterior peak) and OT type (others). The 331 uroflowmetric curves were classified into the above 6 types, and the relationship between each type of flow curve and other uroflowmetric parameters (voided volume = VV, residual urine volume = RU, maximum flow rate = MFR, average flow rate = AFR) was analyzed. The types of 229 flow studies (140 patients) in benign prostatic hypertrophy were OB (77.7%), AP (16.6%), OT (3.9%), N (0.9%) and PP (0.9%). The types of 39 flow studies (25 patients) in prostatic cancer and 13 studies (8 patients) in urethral stricture were similar; 92.3% of the flow studies being classified into OB type. The types of 21 flow studies (10 patients) in so-called bladder neck contraction were OB (42.9%), AP (33.3%), OT (14.3%) and NB (9.5%). AP type flow curves were more frequent than other in obstructive diseases.(ABSTRACT TRUNCATED AT 250 WORDS)

Aged↗
PubMed1985

Detection of circulating adenocarcinoma-associated antigen in the sera of cancer patients with a monoclonal antibody.

The antigen (YH206 antigen) corresponding to the monoclonal antibody (MoAb) YH206 (IgM), which was produced against a lung adenocarcinoma cell line A549, was found to be an extremely high-molecular-weight protein of over 330,000 daltons by means of SDS-PAGE and Western blot analysis. The immunohistological distribution of the antigenic determinant recognized by MoAb YH206 was found to be limited to adenocarcinoma tissues. It was shown by reversed passive hemagglutination assay (RPHA) that the antigen could be detected not only in the spent medium from human lung cancer cell line A549 but also in the sera from cancer patients. Only 3 out of 30 (10%) healthy donors and 4 of 31 (12.9%) patients with benign diseases had serum antigen levels of more than 1/64 dilution. In contrast, 42 of 87 (48.3%) patients with lung cancer and 29 of 50 (58.0%) patients with cancers of the digestive organs had elevated levels of the antigen. As regards the relation between antigen levels and clinical stages of lung cancer, values of more than 1/128 dilution were detected only in patients with stage III or IV disease.

Adenocarcinoma↗
PubMed1985

[Use of urinary hydroxyproline excretion as a marker of bone metastases in prostatic cancer (1)].

Twenty-four hour urinary hydroxyproline and urinary hydroxyproline creatinine ratio was measured without prior dietary restriction in 24 patients with prostatic cancer and 16 patients with benign prostatic hypertrophy. Both were elevated in patients with prostatic cancer with active bone metastases compared to the values of prostatic cancer without bone metastasis and benign prostatic hypertrophy. In these cases, the values of urinary hydroxyproline creatinine ratio were more reliable. The results show that urinary hydroxyproline creatinine ratio is a very sensitive indicator of active bone metastases of prostatic cancer without dietary restriction.

Bone Neoplasms↗
PubMed1985

Effect of gamma-globulin preparations on phagocytic function of whole blood.

Effect of gamma globulin preparations on opsonic activity in whole blood from non-immunodeficiency was studied using chemiluminescence as the parameter of phagocytic function of granulocytes. Poly (ethylene) glycol treated, Fc-intact preparation clearly enhanced chemiluminescence (luminol-dependent) of blood cells phagocytosing zymosan, Escherichia coli (E. coli), or Pseudomonas aeruginosa (P. aeruginosa), but pepsin-treated preparation showed no effect. Whole blood added with intact preparation at the final concentration of 4 mg/ml showed enhanced CL induced by E. coli and P. aeruginosa in many individuals, especially in infancy, although in adult age suppressive effect was often observed. In six patients with pediatric malignancy and three newborns with suspected septicemia, CL induced by E. coli or P. aeruginosa was measured after the administration of 150 mg/kg of intact preparations, and 4/6 of malignancy showed increased CL by E. coli, and all infants showed increased CL by E. coli and P. aeruginosa. These results suggest that intact gamma globulin preparation can increase phagocytic ability of whole blood in non-immunodeficiency via its opsonins, and may justify the administration of intact gamma globulins in non-immunodeficiency for the purpose of treating bacterial infections in some selected cases.

Adult↗
PubMed1985

[Hormonal and clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH.RH ethylamide against prostatic cancer].

The hormonal and clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH.RH ethylamide (Leuprolide, TAP 144) was investigated with 12 prostatic cancer patients. The hormonal studies were performed in 8 patients who were not previously treated by any hormonal therapies including estrogen, castration and others. Serum level of LH and FSH was apparently decreased at the end of 2 weeks after the starting of leuprolide (1 mg/day) subcutaneous injection. At the same time, testosterone level was decreased to the castration level. Clinical efficacy of 1 mg/day of leuprolide was evaluated in 7 patients who were not previously treated. Three of the 4 patients with stage B2 cancer showed a partial response and 1 patient a stable response; and 1 of the 3 patients with stage D2 cancer showed a partial response and patients stable a response. No significant side effects were observed in these 12 patients. These results show that 1 mg/day of leuprolide has the same degree of potency in decreasing the serum testosterone as 20 mg/day.

Aged↗